Johnson & Johnson Enterprise Innovation Inc.

This study is testing whether adding a new nanoparticle injection (NBTXR3) to standard radiation therapy works better for controlling advanced head and neck cancer in elderly patients. It is for people aged 60 and older who cannot safely receive the usual platinum-based chemother…

This early-stage study is testing whether injecting an experimental drug called JNJ-90301900 directly into tumors is safe and helps shrink cancer when given alongside standard chemotherapy and radiation. It will enroll about 30 people with locally advanced head and neck squamous …

This early-stage study is testing a new treatment called JNJ-87704916, which is a modified virus designed to infect and kill cancer cells. It will be injected directly into tumors of patients with advanced solid tumors who have run out of standard treatment options. The main goal…

This early-stage study is testing a new drug called JNJ-86974680 to find safe doses for people with advanced non-small cell lung cancer. Researchers will give the drug alone and combined with an immunotherapy drug and radiation therapy. The main goal is to check for side effects …

This study is testing whether adding an experimental drug called JNJ-90301900 to standard chemotherapy and radiation treatment improves outcomes for people with advanced, inoperable lung cancer. The trial will involve 130 participants who will receive either the standard treatmen…